Edition:
United Kingdom

Proteostasis Therapeutics Inc (PTI.OQ)

PTI.OQ on NASDAQ Stock Exchange Global Market

3.12USD
18 Jan 2019
Change (% chg)

-- (--)
Prev Close
$3.12
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
485,850
52-wk High
$10.38
52-wk Low
$1.72

Latest Key Developments (Source: Significant Developments)

Proteostasis Therapeutics Announces Global License Agreement With Genentech
Monday, 17 Dec 2018 

Dec 17 (Reuters) - Proteostasis Therapeutics Inc ::PROTEOSTASIS THERAPEUTICS ANNOUNCES GLOBAL LICENSE AGREEMENT WITH GENENTECH.PROTEOSTASIS THERAPEUTICS INC - PROTEOSTASIS IS ELIGIBLE TO RECEIVE UPFRONT AND MILESTONE PAYMENTS OF OVER $100 MILLION.PROTEOSTASIS THERAPEUTICS INC - FULL FINANCIAL TERMS, THERAPEUTIC TARGET AND DISEASE AREAS OF FOCUS ARE NOT DISCLOSED.PROTEOSTASIS THERAPEUTICS INC - PROTEOSTASIS IS ELIGIBLE TO RECEIVE TIERED ROYALTIES ON SALES OF MEDICINES RESULTING FROM LICENSE AGREEMENT.  Full Article

Proteostasis Therapeutics Files For Potential Mixed Shelf Offering Of Upto $200 Mln-SEC Filing
Friday, 23 Nov 2018 

Nov 23 (Reuters) - Proteostasis Therapeutics Inc ::PROTEOSTASIS THERAPEUTICS FILES FOR POTENTIAL MIXED SHELF OFFERING OF UPTO $200 MILLION - SEC FILING.  Full Article

Proteostasis Therapeutics Prices Public Offering Of Common Stock
Wednesday, 24 Oct 2018 

Oct 23 (Reuters) - Proteostasis Therapeutics Inc ::PROTEOSTASIS THERAPEUTICS PRICES PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 11.0 MILLION COMMON SHARES PRICED AT $6.75 PER SHARE.  Full Article

Proteostasis Therapeutics Announces Proposed Public Offering Of Common Stock
Monday, 22 Oct 2018 

Oct 22 (Reuters) - Proteostasis Therapeutics Inc ::PROTEOSTASIS THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.PROTEOSTASIS THERAPEUTICS INC - INTENDS TO OFFER 9 MILLION SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.  Full Article

Proteostasis Therapeutics - Co & Astellas Pharma Entered Into Amendment No. 6 To Collaboration & License Agreement
Monday, 23 Apr 2018 

April 23 (Reuters) - Astellas Pharma Inc <4503.T>::PROTEOSTASIS THERAPEUTICS - ON APRIL 20, CO & ASTELLAS PHARMA ENTERED INTO AMENDMENT NO. 6 TO COLLABORATION & LICENSE AGREEMENT DATED NOVEMBER 4, 2014.PROTEOSTASIS THERAPEUTICS SAYS AMENDMENT EXTENDS RESEARCH TERM FOR INITIAL PROJECT UNDER ASTELLAS AGREEMENT TO DEC 4, 2018 - SEC FILING.  Full Article

Proteostasis Therapeutics Prices Public Offering Of 8 Mln Shares At $5/Share
Thursday, 14 Dec 2017 

Dec 13 (Reuters) - Proteostasis Therapeutics Inc ::PROTEOSTASIS THERAPEUTICS PRICES PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 8.00 MILLION COMMON SHARES PRICED AT $5.00PER SHARE.  Full Article

Proteostasis Therapeutics To Sell 7 Mln Shares In Public Offering
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Proteostasis Therapeutics Inc ::PROTEOSTASIS THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.INTENDS TO OFFER AND SELL, 7 MILLION SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.  Full Article

Proteostasis Therapeutics Announces Positive Clinical Results From Cystic FibrosisStudies
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Proteostasis Therapeutics Inc ::PROTEOSTASIS THERAPEUTICS ANNOUNCES POSITIVE CLINICAL RESULTS FROM STUDIES OF PTI-428, PTI-801 AND PTI-808 IN HEALTHY VOLUNTEERS AND PATIENTS WITH CYSTIC FIBROSIS.PROTEOSTASIS THERAPEUTICS INC - 28-DAY STUDY CONTINUES TO CONFIRM SAFETY PROFILE OF PTI-428 IN THAT IT WAS GENERALLY WELL TOLERATED.PROTEOSTASIS THERAPEUTICS INC - PTI-808 WAS FOUND TO BE GENERALLY WELL TOLERATED.PROTEOSTASIS THERAPEUTICS INC - RESULTS OF PTI-428 MEET EFFICACY ENDPOINT IN 28-DAY STUDY IN CF PATIENTS ON BACKGROUND ORKAMBI.  Full Article

Proteostasis Therapeutics Q3 loss per share $0.56
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Proteostasis Therapeutics Inc :Proteostasis Therapeutics reports third quarter 2017 results and provides CF portfolio update.Q3 revenue $1.6 million versus $1.7 million.Qtrly loss per share $0.56 ‍​.  Full Article

Proteostasis Therapeutics to prioritize resources on cystic fibrosis R&D
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Proteostasis Therapeutics Inc :Proteostasis Therapeutics - ‍initiated strategic prioritization to focus resources on research & development of cystic fibrosis programs, among others​.Proteostasis -‍ as part of the initiative, co is reducing headcount dedicated to research from 46% of total workforce to 34%, by eliminating 13 positions​.Proteostasis Therapeutics - ‍resulting estimated annual cost savings related to prioritization, including personnel & other operating costs, is about $3 million​.Proteostasis Therapeutics Inc - ‍expects to incur a one-time cash charge in Q4 of 2017 for severance and other related costs of $0.2 million​.Proteostasis - ‍restructuring is not anticipated to have operational impact on company's existing cf programs and its UPR program with Astellas​.  Full Article

REFILE-Vertex posts positive data from cystic fibrosis triple combo trials

Nov 27 Vertex Pharmaceuticals Inc said on Tuesday that its triple combination therapy showed significant improvement in lung function in patients with cystic fibrosis (CF) in two late-stage clinical studies, sending its shares up 5 percent.